Patent Intelligence · Domain Comparison
BiotechnologyvsGene Editing
Side-by-side comparison across 8 patent dimensions: portfolio size, citation quality, concentration, prosecution speed, claim breadth, expiry opportunity, and filing velocity.
Biotechnology
Patents
285
Citations
52,426
Avg citations
183.3
3yr CAGR
+12.9%
HHI
695
Expiring ≤2029
1.7%
Avg prosecution
42 mo
Avg claims
23.1
Gene Editing
Patents
41
Citations
19,920
Avg citations
485.9
3yr CAGR
0.0%
HHI
1,160
Expiring ≤2029
0.0%
Avg prosecution
47 mo
Avg claims
28.5
Head-to-Head Comparison
| Metric | Biotechnology | Gene Editing |
|---|---|---|
| Total patents | 285▲ | 41 |
| Total citations | 52,426▲ | 19,920 |
| Avg citations/patent | 183.3 | 485.9▲ |
| 3-year CAGR | +12.9%▲ | 0.0% |
| HHI concentration | 695▲ | 1,160 |
| Expiring ≤2029 | 1.7%▲ | 0.0% |
| Avg prosecution (mo) | 42▲ | 47 |
| Avg claims/patent | 23.1 | 28.5▲ |
▲ = higher is better for that metric. HHI: lower = more competitive landscape.
Grant Trend 2015–Present
Patents granted per year by domain.
2016
2018
2020
2022
2024
2026
Domain A
Domain B
Other comparisons